|
SAN FRANCISCO -- Nano Interface Technology, Inc. has
announced that it will be presenting at 10:50AM on June 15, 2005 at Medtech
Insight's Prestigious "Investment In Innovation (In3): A Preview
of Early-Stage Medical Technology Companies" Conference, taking place
June 14-15, 2005 at The Palace Hotel in San Francisco, CA.
Nano Interface Technology, Inc. (NITI) founded in 1997 has developed nanotechnology-derived
economical ultra-pure coatings for orthopedic and dental implants which
FDA has been in quest for many years. The NIH Nanotech review panel validates
NITI's proprietary technology by stating excellent quality of the product
and its enormous clinical benefits. For the last 20 years, the lifespan
of orthopedic and dental implants has been 10-12 years with revision rate
of 17%. The ultra-pure coatings developed by the NITI will increase the
lifespan of these implants from 12 years to 20 years or longer resulting
in significantly reduced revision. It will also reduce the use of high
strength painkillers. The reduction in the revision rate of hip and knee
implants from 17% to 12% has the potential of saving $825M per year in
the US alone. Since this material is currently used in coating of implants,
therefore implants developed using this purer material will easily get
FDA approval without any clinical studies. It will be widely accepted
by the consumers because the cost of these implants will be significantly
lower than the existing cost of such implants.
NITI has completed the research and will market the
products after in vivo studies in the next 3 years. NITI will provide
coatings for orthopedic implants to manufacturers for higher growth in
revenue and plans to license its technology to the existing players in
the dental implants business. The leading dental implants companies have
already contacted NITI for partnership. The worldwide market size of the
orthopedic and dental implants is $15B per year with 15% growth rate.
The growth rate of 15% will increase to 25% due to the longer life expectancy
and several painkillers for arthritis are being pulled out from the market,
resulting in $30B market by 2009. NITI foresees annual revenue of $133
Million by 2012 based on market shares of 1% in orthopedic and 10% in
dental implants. NITI provides excellent opportunity for capturing 70%
of $15B implants' market by providing superior coatings of biomaterials
on the implants, similar to the success of Boston Scientific in $4B stents'
market by providing better coatings of drugs on the stents. The Wall Street
Reporter interviewed the founder of NITI on May 23, 2005 about business
opportunity utilizing NITI's developed products.
Certain statements included in this press release may
constitute forward-looking statements. Medtech Insight, a division of
Windhover Information Inc., is the leading provider of business information
and market intelligence for the medical technology marketplace.
Source: Nano Interface Technology,
Inc.
|